Positive Syphilis Serology With Concurrent Disseminated Talaromycosis marneffei in a Patient With HIV: A Case Report.

Am J Case RepSep 30, 2026 (epub)

Qihuan Wu, Hong Li, Yuwei Xia et al.

✦ AI-curated · Sources linked

Case in brief

A 37-year-old male with HIV presented with a rash and was initially diagnosed with secondary syphilis based on positive serology. After ampicillin treatment failed to improve his condition, he developed fever and cough. Further investigation using targeted next-generation sequencing and blood culture revealed concurrent disseminated Talaromyces marneffei infection. Despite prolonged positive blood cultures, he ultimately achieved a good outcome with antifungal therapy.

Diagnostic / clinical pearl

This case highlights the importance of considering opportunistic infections like Talaromyces marneffei in HIV patients presenting with atypical symptoms, especially when initial treatments fail.

Why it matters

The case underscores the need for timely diagnostic methods such as targeted next-generation sequencing in patients with HIV to avoid misdiagnosis and ensure appropriate management of concurrent infections.

Source

Published in Am J Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.